REGENERON PHARMACEUTICALS (REGN)
US75886F1075 - Common Stock
What's going on in today's session: S&P500 movers
Curious about the top performers within the S&P500 index in the middle of the day on Tuesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer...
2 Top Growth Stocks to Buy on the Dip
Their recent issues are nothing to fret over for investors focused on the long game.
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH
Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal...
Regeneron Announces Investor Conference Presentations
Regeneron Announces Investor Conference Presentations
TARRYTOWN, N.Y., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: ...
Is It Time to Buy October's Worst-Performing Nasdaq Stocks?
Is it a good time to scoop up last month's biggest losers? Check out October's largest price drops on the Nasdaq, and see whether any of them look like good buys today.
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 weeks...
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
The major indexes declined, but haven't fallen apart.
Thursday Sector Laggards: Technology & Communications, Healthcare
Noteworthy Thursday Option Activity: REGN, DVA, ETR
REGN December 13th Options Begin Trading
Regeneron Earnings Top Views For Biotech Giant
Shares of the biotech giant have been in a sharp slide.
Regeneron Reports Third Quarter 2024 Financial and Operating Results
Regeneron Reports Third Quarter 2024 Financial and Operating Results
Third quarter 2024 revenues increased 11% to $3.72 billion versus third quarter 2023Third quarter 2024 Dupixent® global net sales (recorded by Sanofi)...
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
One of these players has split its stock in the past. The other one hasn't.